Adicet Bio, Inc. (ACET): restructuring charge — Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026

Adicet Bio, Inc.

Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.
Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).
ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.
Restructuring and program cuts expected to extend cash runway into Q4 2026.
ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Adicet Bio, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 30% of the Company’s current employee base).

Type: restructuring
Charge: approximately $2.3 million
Headcount: approximately 30% of the Company’s current employee base

Exact text from the filing

On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under Item 8.01 of this Current Report on Form 8-K. This workforce reduction will be substantially completed by the end of the third quarter of 2025. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $2.3 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the third quarter of 2025.

View on SEC.gov

Browse all restructurings & charges →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-097881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.